Stocks / NASDAQ / CTI BioPharma Corp.

CTI BioPharma Corp.

Our Opinion

CTI BioPharma Corp. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

“For Pacritinib, Ruxolitinib, and Tofacitinib, pivotal nonclinical studies were performed in one rodent model and one non-rodent large animal model.  The goal of these studies was to identify a no adverse effect level (NOAEL), if possible,  and to characterize toxicities anticipated above that dose.”

Company Description

CTI BioPharma Corp. operates as a biopharmaceutical company, which is focuses on the development, acquisition, and commercialization of novel treatments for cancer. Its products include Pixuvri, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. [Source: MarketWatch]

Company Website: